Hit Identification and High Throughput Screening
Successful drug discovery requires solid foundations
Aptuit has a flexible range of strategies proven to deliver successful and effective drug discovery projects. Our Hit Identification capabilities are spread over all disciplines, including computational and medicinal chemistry, DMPK, Pharmacology and Analytical Sciences. Aptuit’s Hit discovery teams perform High Throughput Screening (HTS) and Hit profiling using the Aptuit Screening Collection (>400k molecules).
At our Verona and Basel facilities, dedicated scientists are implementing new screening technologies that complement and enhance our already robust suite of capabilities. Our compound collection has delivered promising Hit series for numerous customers, and has been recently expanded and improved to further enhance Hit series identification across a wide range of therapeutic areas.
Plus, we offer an alternative range of virtual screening approaches that can be used in tandem with High Throughput Screening in early drug discovery.
Our capabilities include rapid evaluation of Hits based on a series of experimental data:
- Structure ID and purity determination
- Ligand/target interaction determination, in vitro activity and MoA
- In vitro selectivity and specificity
- Analysis of chemical tractability
- Hit expansion by prospective chemistry
- In vitro blood and tissue binding
- Preliminary in vitro DMPK profiling
Aptuit offers a comprehensive range of capabilities supporting and enabling the assay generation (functional and bio-chemical) phase – including generation of biological reagents and cell lines.